The University of Kansas Cancer Center, Westwood Campus

Kansas City, Kansas 66205

5 studies enrolling now · 21 studies all time

What they study most

Basal Cell Carcinoma, Bladder Cancer, Breast Cancer, Breast Cancer Metastatic, Colon Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Digestive Cancer, Esophagus Cancer, Adenocarcinoma, HER2-positive Breast Cancer, Locally Advanced Lung Carcinoma, Lung Cancer

Studies at this site

• Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC — Recruiting now
• Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer — Recruiting now
• Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients — Recruiting now
• Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC — Recruiting now
• Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer — Recruiting now
• Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients — Running, not enrolling
• CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab — Running, not enrolling
• Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer — Status unconfirmed
• Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer — Stopped early
• Measuring Taste Perception During Chemotherapy for Muscle Invasive Bladder Cancer — Status unconfirmed
• Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate — Withdrawn before enrolling
• Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate — Stopped early
• Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) — Status unconfirmed
• Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy — Status unconfirmed
• Efficacy of Point Of Service Testing in MBC — Status unconfirmed
• Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) — Status unconfirmed
• A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors — Status unconfirmed
• To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment — Status unconfirmed
• Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas — Withdrawn before enrolling
• Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma — Status unconfirmed
• Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer — Status unconfirmed